LIPUM Stock Overview
A biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lipum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 12.00 |
| 52 Week High | SEK 15.00 |
| 52 Week Low | SEK 5.50 |
| Beta | 0.036 |
| 11 Month Change | 42.01% |
| 3 Month Change | 80.45% |
| 1 Year Change | 34.23% |
| 33 Year Change | -51.61% |
| 5 Year Change | n/a |
| Change since IPO | -47.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| LIPUM | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 14.3% | -2.4% | -4.3% |
| 1Y | 34.2% | 18.0% | 12.6% |
Return vs Industry: LIPUM exceeded the Swedish Biotechs industry which returned 18.1% over the past year.
Return vs Market: LIPUM exceeded the Swedish Market which returned 12.5% over the past year.
Price Volatility
| LIPUM volatility | |
|---|---|
| LIPUM Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: LIPUM's share price has been volatile over the past 3 months.
Volatility Over Time: LIPUM's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5 | Ola Sandborgh | www.lipum.se |
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular.
Lipum AB (publ) Fundamentals Summary
| LIPUM fundamental statistics | |
|---|---|
| Market cap | SEK 254.55m |
| Earnings (TTM) | -SEK 39.32m |
| Revenue (TTM) | SEK 53.00k |
4,803x
P/S Ratio-6.5x
P/E RatioIs LIPUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPUM income statement (TTM) | |
|---|---|
| Revenue | SEK 53.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 53.00k |
| Other Expenses | SEK 39.37m |
| Earnings | -SEK 39.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 100.00% |
| Net Profit Margin | -74,184.91% |
| Debt/Equity Ratio | -37.1% |
How did LIPUM perform over the long term?
See historical performance and comparison